106190 — High Tech Pharm Co Balance Sheet
0.000.00%
- KR₩142bn
- KR₩143bn
- KR₩78bn
- 75
- 54
- 27
- 53
Annual balance sheet for High Tech Pharm Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 1,038 | 12,637 | 7,880 | 5,365 | 7,759 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 19,708 | 9,472 | 28,555 | 24,483 | 20,357 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Current Assets | 40,477 | 40,488 | 52,040 | 56,571 | 64,234 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 85,205 | 80,544 | 74,934 | 75,001 | 72,002 |
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 128,446 | 122,937 | 132,202 | 135,058 | 140,090 |
Accounts Payable | |||||
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 26,933 | 22,703 | 31,738 | 22,785 | 18,946 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 33,302 | 29,052 | 32,263 | 28,064 | 20,352 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Total Equity | 95,144 | 93,885 | 99,939 | 106,994 | 119,738 |
Total Liabilities & Shareholders' Equity | 128,446 | 122,937 | 132,202 | 135,058 | 140,090 |
Total Common Shares Outstanding |